Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Emerging Treatments and Signaling Pathway Inhibitors SEMINARS IN CUTANEOUS MEDICINE AND SURGERY Tang, J. Y., Marghoob, A. A. 2011; 30 (4): S14-S18

Abstract

A number of therapies that target components of the Hedgehog signaling pathway currently are in clinical trials. The specific molecules that seem most promising in basal cell carcinoma and a number of other cancers are those that target the Smoothened transmembrane protein. The pivotal phase II trials have been completed on the Smoothened inhibitor known as GDC-0449; five other agents (BMS-833923, LDE225, LEQ506, IPI926, and TAK-441) have also shown promise in animal studies and early clinical trials and have shown some efficacy in a variety of cancers that are affected by the Hedgehog signaling pathway.

View details for DOI 10.1016/j.sder.2011.11.002

View details for Web of Science ID 000298710300004

View details for PubMedID 22177102